Attached files
EXHIBIT 99.1
| Contact: |
Robert T.
Yurckonis
Chief Executive
Officer
941-780-2362
E-mail: tyler812@comcast.net
|
| For Immediate Release | Monday March 1, 2010 |
Equinox
International to Acquire Innovative Medical Technology
LAS
VEGAS, March 1, 2010 (GLOBE NEWSWIRE) – Equinox International (OTCBB: EQNX)
(the “Company”) has entered into a binding agreement to acquire certain
exclusive technology rights of Biostem US L.L.C., a Florida medical technology
company, for a controlling interest in stock of the Company. The
transaction has received stockholder approval and will close as soon as all
regulatory requirements have been satisfied. Said Tyler Yurckonis, the
Company’s CEO, “This transaction represents an opportunity for us to create
significant value for our shareholders, and we are extremely excited about the
prospects for Biostem technology and methods the Company will soon introduce to
the medical marketplace.”
About the
Company
EQNX is a
development stage company with non-operating interests in two producing oil and
gas wells in Alberta, Canada that has been seeking to raise capital to acquire
additional interests in producing and development stage oil and gas exploration
wells with exploration potential.
About
Biostem US L.L.C.
Founded
earlier this year by researcher John Satino and Dr. Michael Markou, of
Clearwater, Florida, Biostem US L.L.C. has proprietary technology and methods
that represent a new and improved approach to treating hair loss, by utilizing
platelets derived from a patient’s own stem cells, injected in the scalp, to
stimulate hair growth. It is expected that the Biostem technology and methods to
be acquired by the Company will be adopted by more than 15 hair loss clinics
across the United States in the coming three months.
CONTACT: Equinox
International
Robert T. Yurckonis, Chief Executive Officer
941-780-2362
tyler812@comcast.net
Robert T. Yurckonis, Chief Executive Officer
941-780-2362
tyler812@comcast.net